Golden State Wealth Management LLC Has $466,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Golden State Wealth Management LLC boosted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2,889.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,033 shares of the medical instruments supplier's stock after buying an additional 1,965 shares during the quarter. Golden State Wealth Management LLC's holdings in Becton, Dickinson and Company were worth $466,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of BDX. Hillsdale Investment Management Inc. lifted its position in shares of Becton, Dickinson and Company by 1.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock worth $694,000 after purchasing an additional 50 shares in the last quarter. Alpha Omega Wealth Management LLC increased its stake in Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock valued at $225,000 after buying an additional 53 shares during the last quarter. Brady Family Wealth LLC lifted its position in Becton, Dickinson and Company by 1.2% during the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after buying an additional 53 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 54 shares during the last quarter. Finally, REAP Financial Group LLC grew its holdings in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Institutional investors own 86.97% of the company's stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP David Shan sold 1,166 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president now directly owns 4,575 shares in the company, valued at $783,194.25. This represents a 20.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the transaction, the executive vice president now directly owns 4,887 shares of the company's stock, valued at approximately $964,107.36. The trade was a 8.93% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded up $0.86 on Friday, reaching $170.83. The stock had a trading volume of 3,070,304 shares, compared to its average volume of 2,034,006. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The company has a market cap of $48.96 billion, a P/E ratio of 32.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.25. The firm has a fifty day moving average of $177.09 and a two-hundred day moving average of $209.86.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. Becton, Dickinson and Company's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the firm earned $3.17 earnings per share. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.44%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BDX. Stifel Nicolaus reduced their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Wall Street Zen downgraded Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Barclays lowered their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Wells Fargo & Company cut shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Finally, William Blair cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.